US Postal Service seeks DOGE team help on retail leases, counterfeit postage
Canada reviews US fighter jet deal but alternatives look costly
Red Sea insurance rates to stay firm as US airstrikes raise fears for ships
Ukraine and Russia have conditions that could affect a ceasefire. What are they willing to concede?
Volkswagen's Audi to cut 7,500 jobs in administration, development by 2029
Conan O'Brien to return as Oscars host in 2026
Drake's label says lawsuit over Lamar's 'Not Like Us' should be dismissed
87-year-old mows grass by day, impersonates Elvis by night
JERUSALEM (Reuters) - Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, chief executive Richard Francis said on Wednesday.
"Our job, as always, is to work productively with any administration, and we've shown we can do that, and we will absolutely do that," Francis told Reuters after the Israeli drugmaker issued strong third-quarter results.
He said, though, it wouldn't be clear until after Donald Trump takes office what his healthcare and pharmaceutical policies will be.
Francis also said that he expects 2025 to be "more of the same" for the company, with growth in branded drugs, continuing growth in its generics drugs business, plus more sales of biosimilars.
(Reporting by Steven Scheer; Editing by Mark Potter)
